Acrivon Therapeutics reported total assets of $99.09M and total liabilities of $12.43M for the quarter ended Jun 2026, down 37.5% year over year. This balance sheet covers 20 quarters of results from Sep 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 0.06M | 0.29M | 0.42M | 0.55M | 0.67M | 0.81M | 0.96M | 1.18M | 1.41M | 1.66M | 1.96M | 2.27M | 2.61M | 2.96M | 3.32M | 3.70M | 4.11M | |||
| Assets | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 3.61M | 99.60M | 90.77M | 83.86M | 32.08M | 29.52M | 27.49M | 38.07M | 29.86M | 36.02M | 24.61M | 46.01M | 43.41M | 39.82M | 39.15M | 41.90M | 35.41M | 41.50M | 34.06M | 41.42M |
| Prepaid Assets | 0.81M | 1.85M | 4.34M | 3.75M | 2.33M | 2.40M | 2.23M | 2.17M | 1.82M | 1.53M | 2.15M | 1.69M | 0.99M | 1.11M | 1.86M | 1.48M | 1.53M | |||
| Current Assets | 100.41M | 78.67M | 132.09M | 123.96M | 153.28M | 144.49M | 129.69M | 112.14M | 182.36M | 188.98M | 181.63M | 151.33M | 138.41M | 130.36M | 120.44M | 99.22M | 91.49M | |||
| Non-Current Assets | ||||||||||||||||||||
| Property, Plant & Equipment (Net) | 0.29M | 2.15M | 2.09M | 1.99M | 1.98M | 2.00M | 3.48M | 3.41M | 3.47M | 4.67M | 4.47M | 4.68M | 5.07M | 5.19M | 4.89M | 4.65M | 4.25M | |||
| Long-Term Investments | 41.88M | 39.27M | 39.90M | 15.39M | 5.09M | 15.20M | 10.20M | 5.11M | ||||||||||||
| Other Non-Current Assets | 0.39M | 1.54M | 0.39M | 0.39M | 0.41M | 0.41M | 0.41M | 0.42M | 0.47M | 1.18M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.51M | 1.18M | |||
| Non-Current Assets | 6.18M | 9.04M | 49.13M | 46.23M | 6.77M | 6.60M | 8.57M | 8.38M | 48.23M | 25.70M | 14.96M | 25.02M | 20.17M | 14.94M | 9.27M | 8.61M | 7.60M | |||
| Assets | 106.59M | 87.71M | 181.23M | 170.20M | 160.05M | 151.09M | 138.26M | 120.52M | 230.59M | 214.68M | 196.59M | 176.35M | 158.58M | 145.30M | 129.72M | 107.83M | 99.09M | |||
| Liabilities | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts Payables | 0.96M | 1.98M | 0.90M | 1.37M | 1.27M | 1.50M | 5.05M | 2.06M | 1.26M | 1.51M | 0.76M | 3.69M | 1.16M | 1.00M | 2.28M | 1.16M | 0.86M | |||
| Payables | 0.96M | 1.98M | 0.90M | 1.37M | 1.27M | 1.50M | 5.05M | 2.06M | 1.26M | 1.51M | 0.76M | 3.69M | 1.16M | 1.00M | 2.28M | 1.16M | 0.86M | |||
| Accumulated Expenses | 1.29M | 3.70M | 4.89M | 3.57M | 5.00M | 7.02M | 7.38M | 6.04M | 9.04M | 12.27M | 15.40M | 8.75M | 11.12M | 12.71M | 12.21M | 8.74M | 9.45M | |||
| Other Accumulated Expenses | 0.41M | 1.10M | 0.79M | 1.41M | 2.05M | 2.92M | 2.66M | 3.42M | 5.07M | 7.54M | 9.25M | 5.58M | 6.84M | 7.88M | 5.96M | 5.54M | 4.77M | |||
| Total Current Liabilities | 2.91M | 6.39M | 6.52M | 5.68M | 7.02M | 9.30M | 13.30M | 9.04M | 11.28M | 14.82M | 17.21M | 13.55M | 13.43M | 14.89M | 15.66M | 11.05M | 11.45M | |||
| Non-Current Liabilities | ||||||||||||||||||||
| Preferred Stock Liabilities | 22.50M | 122.52M | 122.52M | 122.52M | 122.52M | |||||||||||||||
| Operating Leases | 4.96M | 4.42M | 4.24M | 4.05M | 3.85M | 3.64M | 3.77M | 3.50M | 3.24M | 2.97M | 2.59M | 2.41M | 2.12M | 1.80M | 1.54M | 1.26M | 0.98M | |||
| Total Liabilities | 130.40M | 133.33M | 10.75M | 9.73M | 10.87M | 12.94M | 17.07M | 12.54M | 14.53M | 17.79M | 19.80M | 15.96M | 15.55M | 16.70M | 17.20M | 12.32M | 12.43M | |||
| Shareholder's Equity | ||||||||||||||||||||
| Common Equity | -19.77M | -23.81M | -30.99M | -36.58M | -45.62M | 170.47M | 160.47M | 149.18M | 138.15M | 121.19M | 107.98M | 216.06M | 196.89M | 176.79M | 160.39M | 143.04M | 128.60M | 112.52M | 95.52M | 86.67M |
| Liabilities and Shareholders Equity | 106.59M | 87.71M | 181.23M | 170.20M | 160.05M | 151.09M | 138.26M | 120.52M | 230.59M | 214.68M | 196.59M | 176.35M | 158.58M | 145.30M | 129.72M | 107.83M | 99.09M | |||
| Retained Earnings | -24.90M | -47.10M | -56.03M | -116.40M | -82.70M | -97.20M | -116.42M | -132.91M | -151.70M | -174.15M | -197.00M | -216.70M | -237.70M | -255.90M | -274.88M | -293.92M | -311.90M |
Pull Acrivon Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ACRV&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ACRV", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ACRV&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();